The Expanding Role of MRI in Prostate Cancer : American Journal of Roentgenology : Vol. 201, No. 6 (AJR)

December 2013, Volume 201, Number 6

« Previous Article | Next Article »

Genitourinary Imaging

Review

The Expanding Role of MRI in Prostate Cancer

Gillian Murphy¹, Masoom Haider², Sangeet Ghai¹ and Boraiah Sreeharsha²

Share Claim CME/SAM

+ Affiliations:

¹ Joint Department of Medical Imaging, Toronto General Hospital, 200 Elizabeth St, Toronto, ON, Canada M5G 2C4.

² Joint Department of Medical Imaging, Princess Margaret Hospital, Toronto, ON, Canada

Citation: American Journal of Roentgenology. 2013;201: 1229-1238. 10.2214/AJR.12.10178

ABSTRACT :

OBJECTIVE. The purpose of this article is to review the many evolving facets of MRI in the evaluation of prostate cancer. We will discuss the roles of multiparametric MRI, including diffusion-weighted MRI, dynamic contrast-enhanced MRI, and MR spectroscopy, as adjuncts to morphologic T2-weighted imaging in detection, staging, treatment planning, and surveillance of prostate cancer.

CONCLUSION. Radiologists need to understand the advantages, limitations, and potential pitfalls of the different sequences to provide optimal assessment of prostate cancer.

Keywords: multiparametric MRI, prostate biopsy, prostate cancer

Presented as a poster at the 2012 annual meeting of the ARRS and awarded the ARRS 2012 Certificate of Merit.

References

1. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22:746–757 [Google Scholar]

2. Hambrock T, Somford DM, Hoeks C, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010; 183:520–528 [Google Scholar]

3. Ahmed HU, Kirkham A, Arya M, et al. Is it time to consider a role for MRI before prostate biopsy. Nat Rev Clin Oncol 2009; 6:197–206 [Google Scholar]

4. Costouros NG, Coakley FV, Westphalen AC, et al. Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging. AJR 2007; 188:812–816 [Abstract] [Google Scholar]

5. Bonekamp D, Jacobs MA, El-Khouli R, Stoianovici D, Macura KJ. Advancements in MR imaging of the prostate: from diagnosis to interventions. RadioGraphics 2011; 31:677–703 [Google Scholar]

6. Freedland SJ, Kane CJ, Amling CL, et al. Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology 2007; 69:495–499 [Google Scholar]

7. Lawrentschuk N, Haider MA, Daljeet N, et al. ‘Prostatic evasive anterior tumours’: the role of magnetic resonance imaging. BJU Int 2010; 105:1231–1236 [Google Scholar]

8. Park BK, Park JW, Park SY, et al. Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound–guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy. AJR 2011; 197:[web]W876–W881 [Abstract] [Google Scholar]

9. Natarajan S, Marks LS, Margolis DJ, et al. Clinical application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol 2011; 29:334–342 [Google Scholar]

10. Pinto PA, Chung PH, Rastinehad AR, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011; 186:1281–1285 [Google Scholar]

11. Porten SP, Whitson JM, Cowan JE, et al. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol 2011; 10:29:2795–2800 [Google Scholar]

12. Sheridan TB, Carter HB, Wang W, et al. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol 2008; 179:901–904 [Google Scholar]

13. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28:126–131 [Google Scholar]

14. Berglund RK, Masterson TA, Vora KC, et al. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 2008; 180:1964–1967 [Google Scholar]

15. Eggener SE, Mueller A, Berglund RK, et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 2009; 181:1635–1641 [Google Scholar]

16. van den Bergh RC, Vasarainen H, van der Poel HG, et al. Short-term outcomes of the prospective multicentre ‘Prostate Cancer Res International: Active Surveillance’ study. BJU Int 2010; 105:956–962 [Google Scholar]

17. Claus FG, Hricak H, Hattery RR. Pretreatment evaluation of prostate cancer: role of MR imaging and ¹H MR spectroscopy. RadioGraphics 2004; 24(suppl 1):S167–S180 [Google Scholar]

18. Choi YJ, Kim JK, Kim N, Kim KW, Choi EK, Cho KS. Functional MR imaging of prostate cancer. RadioGraphics 2007; 27:63–77 [Google Scholar]

19. Verma S, Turkbey B, Muradyan N, et al. Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR 2012; 198:1277–1288 [Abstract] [Google Scholar]

20. Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011; 59:477–494 [Google Scholar]

21. Wang L, Hricak H, Kattan MW, Chen HN, Scardino PT, Kuroiwa K. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 2006; 238:597–603 [Google Scholar]

22. Beyersdorff D, Taymoonan K, Knösel T, et al. MRI of prostate cancer at 1.5 and 3.0 T: comparison of image quality in tumor detection and staging. AJR 2005; 185:1214–1220 [Abstract] [Google Scholar]

23. Porcaro AB, Borsato A, Romano M, et al. Accuracy of preoperative endorectal coil magnetic resonance imaging in detecting clinical under-staging of localized prostate cancer. World J Urol 2012; [Epub 2012 Jul 7] [Google Scholar]

24. Bloch BN, Genega EM, Costa DN, et al. Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI. Eur Radiol 2012; 22:2201–2210 [Google Scholar]

25. Muglia VF, Westphalen AC, Wang ZJ, Kurhanewicz J, Carroll PR, Coakley FV. Endorectal MRI of prostate cancer: incremental prognostic importance of gross locally advanced disease. AJR 2011; 197:1369–1374 [Abstract] [Google Scholar]

26. Wang L, Hricak H, Kattan MW, et al. Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR 2006; 186:743–748 [Abstract] [Google Scholar]

27. Carroll PR, Coakley FV, Kurhanewicz J. Magnetic resonance imaging and spectroscopy of prostate cancer. Rev Urol 2006; 8(suppl 1):S4–S10 [Google Scholar]

28. Hricak H, Wang L, Wei DC, et al. The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer 2004; 100:2655–2663 [Google Scholar]

29. McClure TD, Margolis DJ, Reiter RE, et al. Use of MR imaging to determine preservation of the neurovascular bundles at robotic-assisted laparoscopic prostatectomy. Radiology 2012; 262:874–883 [Google Scholar]

30. Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR 2007; 189:323–328 [Abstract] [Google Scholar]

31. Rosenkrantz AB, Scionti SM, Mendrinos S, Taneja SS. Role of MRI in minimally invasive focal ablative therapy for prostate cancer. AJR 2011; 197:[web]W90–W96 [Abstract] [Google Scholar]

32. Wassberg C, Akin O, Vargas HA, Shukla-Dave A, Zhang J, Hricak H. The incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience. AJR 2012; 199:360–366 [Abstract] [Google Scholar]

33. Silverman JM, Krebs TL. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR 1997; 168:379–385 [Abstract] [Google Scholar]

34. Sella T, Schwartz LH, Swindle PV, et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004; 231:379–385 [Google Scholar]

35. Casciani E, Polettini E, Carmenini E, et al. Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR 2008; 190:1187–1192 [Abstract] [Google Scholar]

36. Cirillo S, Petracchini M, Scotti L, et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 2009; 19:761–769 [Google Scholar]

37. Sciarra A, Panebianco V, Salciccia S, et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 2008; 54:589–600 [Google Scholar]

38. Morgan VA, Riches SF, Giles S, Dearnaley D, de-Souza NM. Diffusion-weighted MRI for locally recurrent prostate cancer after external beam radiotherapy. AJR 2012; 198:596–602 [Abstract] [Google Scholar]

39. Tamada T, Sone T, Jo Y, et al. Locally recurrent prostate cancer after high-dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging in localizing tumors. AJR 2011; 197:408–414 [Abstract] [Google Scholar]

40. Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70:425–430 [Google Scholar]

41. Turkbey B, Mani H, Shah V, et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 2011; 186:1818–1824 [Google Scholar]

42. Tamada T, Sone T, Higashi H, et al. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4–10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. AJR 2011; 197:664–670 [Abstract] [Google Scholar]

43. Ocak I, Bernardo M, Metzger G, et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR 2007; 189:[web]W192–W201 [Abstract] [Google Scholar]

44. Cohen RJ, Shannon BA, Phillips M, Moorin RE, Wheeler TM, Garrett KL. Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features. J Urol 2008; 179:1762–1767 [Google Scholar]

45. Kim JK, Hong SS, Choi YJ, et al. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging 2005; 22:639–646 [Google Scholar]

46. Iwazawa J, Mitani T, Sassa S, Ohue S. Prostate cancer detection with MRI: is dynamic contrast-enhanced imaging necessary in addition to diffusion-weighted imaging? Diagn Interv Radiol 2011; 17:243–248 [Google Scholar]

47. Malayeri AA, El Khouli RH, Zaheer A, et al. Principles and applications of diffusion-weighted imaging in cancer detection, staging, and treatment follow-up. RadioGraphics 2011; 31:1773–1791 [Google Scholar]

48. Wu LM, Xu JR, Ye YQ, Lu Q, Hu JN. The clinical value of diffusion-weighted imaging in combination with T2-weighted imaging in diagnosing prostate carcinoma: a systematic review and meta-analysis. AJR 2012; 199:103–110 [Abstract] [Google Scholar]

49. Wetter A, Engl TA, Nadjmabadi D, et al. Combined MRI and MR spectroscopy of the prostate before radical prostatectomy. AJR 2006; 187:724–730 [Abstract] [Google Scholar]

50. Verma S, Rajesh A, Fütterer JJ, et al. Prostate MRI and 3D MR spectroscopy: how we do it. AJR 2010; 194:1414–1426 [Abstract] [Google Scholar]

Address correspondence to G. Murphy ([email protected]).